System and method for optogenetic therapy
Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
1. A method for creating a directed action potential in a targeted nerve comprising light sensitive protein, comprising:
a. providing a light source;
b. providing an implantable optical applicator configured to engage the targeted nerve and to deliver light to the targeted nerve, the implantable optical applicator operatively coupled to the light source and configured to deliver photons to the implantable optical applicator which may be emitted by the implantable optical applicator into the targeted nerve to cause a membrane polarization change in the targeted nerve;
c. providing a power source;
d. providing an implantable electrical stimulation applicator configured to engage the targeted nerve, the implantable electrical stimulation applicator operatively coupled to the power source and configured to deliver electrons to the implantable electrical stimulation applicator which may be emitted by the implantable electrical stimulation applicator into the targeted nerve to cause a membrane polarization change in the targeted nerve; and
e. operatively coupling a controller to the light source and the power source, the controller configured to cause both current to flow to the implantable electrical stimulation applicator and photons to be directed to the implantable optical applicator, such that an action potential is created which propagates in a first desired direction along the nerve, and which does not substantially propagate in a reverse direction along the nerve.
2. The method of claim 1 , further comprising serially coupling the implantable optical applicator and implantable electrical applicator are serially to the nerve with the implantable optical applicator positioned closer to the spinal cord than the implantable electrical applicator.
3. The method of claim 2 , further comprising genetically modifying the nerve to encode an opsin protein.
4. The method of claim 3 , wherein the opsin protein is an inhibitory opsin protein.
5. The method of claim 4 , wherein the inhibitory opsin protein is selected from the group consisting of: NpHR, eNpHR 1.0, eNpHR 2.0, eNpHR 3.0, Mac, Mac 3.0, Arch, and ArchT.
6. The method of claim 3 , wherein the opsin protein is a stimulatory opsin protein.
7. The method of claim 4 , wherein the stimulatory opsin protein is selected from the group consisting of: ChR2, C1V1-T, C1V1-TT, CatCh, VChR1-SFO, and ChR2-SFO.
8. The method of claim 7 , further comprising configuring the controller to cause the light source to create an action potential directed toward the spinal cord, while also causing the power source to hyperstimulate the implantable electrical applicator to cause inhibition of an action potential in the opposite direction away from the spinal cord.
9. The method of claim 7 , further comprising configuring the controller to cause the light source to create a hyperstimulation block toward the spinal cord, while also causing the power source to stimulate the implantable electrical applicator to create an action potential directed in the opposite direction away from the spinal cord.
10. The method of claim 4 , further comprising configuring the controller to cause the light source to inhibit action potentials toward the spinal cord, while also causing the power source to stimulate the implantable electrical applicator to create an action potential directed in the opposite direction away from the spinal cord.
11. The method of claim 1 , further comprising serially coupling the implantable optical applicator and implantable electrical applicator to the nerve with the implantable electrical applicator positioned closer to the spinal cord than the implantable optical applicator.
12. The method of claim 11 , further comprising genetically modifying the nerve to encode an opsin protein.
13. The method of claim 12 , wherein the opsin protein is an inhibitory opsin protein.
14. The method of claim 13 , wherein the inhibitory opsin protein is selected from the group consisting of: NpHR, eNpHR 1.0, eNpHR 2.0, eNpHR 3.0, Mac, Mac 3.0, Arch, and ArchT.
15. The method of claim 12 , wherein the opsin protein is a stimulatory opsin protein.
16. The method of claim 13 , wherein the stimulatory opsin protein is selected from the group consisting of: ChR2, C1V1-T, C1V1-TT, CatCh, VChR1-SFO, and ChR2-SFO.
17. The method of claim 16 , further comprising configuring the controller to cause the light source to create an action potential directed away from the spinal cord, while also causing the power source to hyperstimulate the implantable electrical applicator to cause inhibition of an action potential in the opposite direction toward the spinal cord.
18. The method of claim 16 , further comprising configuring the controller to cause the light source to create a hyperstimulation block away from the spinal cord, while also causing the power source to stimulate the implantable electrical applicator to create an action potential directed in the opposite direction toward the spinal cord.
19. The method of claim 13 , further comprising configuring the controller to cause the light source to inhibit action potentials away from the spinal cord, while also causing the power source to stimulate the implantable electrical applicator to create an action potential directed in the opposite direction toward the spinal cord.